56 results about "Choleretic" patented technology

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.

Compounds of general formula (I): wherein R2a, R2b, R3a, R3b, R5, Y and R7 are as defined herein are selective agonists at the FXR receptor and are useful for the treatment or prevention of diseases and conditions including nonalcoholic steatohepatitis (NASH); primary biliary cirrhosis; primary sclerosing cholangitis; biliary atresia; cholestatic liver disease; hepatitis C infection; alcoholic liver disease; fibrosis; or liver damage arising from fibrosis.

The invention belongs to the technical field of medicine, and specifically relates to compounds represented by formula (I), pharmaceutically acceptable salts, esters or stereoisomers thereof, R 1 , R 2 , R 3 , R 4 , W, A, Z, E, X, Y, n are as defined in the description and claims; the present invention also relates to the preparation methods, pharmaceutical preparations and preparation of these compounds for the treatment and / or prevention of FXR receptor The application of drugs in related diseases such as non-alcoholic fatty liver, primary biliary cirrhosis, lipid metabolism disorders, diabetic complications and malignant tumors.

The invention belongs to the field of medical detection, and relates to a serum exosome PIGR, specifically to a use for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitisand predicting curative effect. The technical solution adopted by the invention is a kit for using serum exosome pIgR as a marker for diagnosing primary biliary cholangitis and predicting curative effect, which is characterized by including the following components: a pIgR standard, a polystyrene ELISA (Enzyme Linked Immunosorbent Assay) microplate coated with pIgR antigens, a second enzyme-labeled antibody, a sample diluent, and an auxiliary reagent. The technical solution of the application method of the kit includes the following steps of: (1) preparing the sample diluent; (2) diluting thepIgR standard with a BSA-PBS solution into 8 gradients; (3) adding the standard and the sample diluent to a microplate; (4) adding the second enzyme-labeled antibody to each well; (5) adding a color developing liquid to each well; and (6) using a microplate reader to read an OD value at a wavelength of 450 nm , drawing a standard curve, and converting pIgR concentration in the sample. New kits andapplications are implemented by employing the above schemes.

Provided are compounds of Formula (I):The compounds target the lanthionine synthetase C-like (LANCL) family of proteins, including LANCL2 and LANCL3. The compounds can be used to treat conditions such as inflammatory diseases, metabolic diseases, autoimmune diseases, cancers, and infectious diseases. Exemplary conditions include inflammatory conditions of the liver, such as nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and cirrhosis; inflammatory conditions of the bile duct, such as primary biliary cholangitis, primary sclerosing cholangitis; inflammatory bowel disease, such as Crohn's disease and ulcerative colitis; lupus, such as systemic lupus erythematosus, lupus nephritis, and cutaneous lupus; arthritis, such as rheumatoid arthritis; hyperglycemia, such as type 1 diabetes, type 2 diabetes, and prediabetes and associated conditions such as atherosclerosis and diabetic kidney disease; psoriasis; and multiple sclerosis.

Disclosed are antagonists of PC3-secreted microprotein (PSMP) and use of the antagonists for treatment of liver, lung, or kidney fibrosis, including various diseases or disorders associated with liver, lung, or kidney fibrosis such as, e.g., non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), primary sclerosing cholangitis (PSC), primary biliary cholangitis (PBC), drug-induced lung injury, acute kidney injury (AKI), chronic kidney disease (CKD), lupus nephritis, IgA nephropathy, and membranous glomerulonephritis. Also disclosed are PSMP antagonists and their use for treatment of graft-versus-host disease (GVHD) and systemic lupus erythematosus (SLE). Suitable PSMP antagonists for use in disease treatment include PSMP-binding proteins such as, for example, neutralizing anti-PSMP antibodies.

The invention relates to uses of polypeptide compounds having dual target agonist effect on glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR), characterized by high enzymolysis stability, high biological activity and no adverse reaction. The polypeptide compounds are able to significantly improve a degree of BDL-induced cholestasis hepatic fibrosis in rats, and have significant therapeutic effects on diseases such as biliary cirrhosis. The dual target agonist polypeptides are applicable to the prevention or treatment of biliary cirrhosis and related hepatic fibrosis diseases.

The invention relates to a traditional Chinese medicine compound preparation with effects of benefiting gallbladder and harmonizing stomach, and invigorating blood circulation and eliminating dampness and a use thereof. The traditional Chinese medicine compound preparation is prepared from rhizoma panacis japonica, gentrin knotweed, processed rhizoma pinelliae, loquat leaf, poria cocos, lily and radish seeds. The traditional Chinese medicine compound preparation has effects of benefiting gallbladder and harmonizing stomach, and invigorating blood circulation and eliminating dampness. A pharmacological study proves that the traditional Chinese medicine compound preparation can be used for treating chronic gastritis such as chronic superficial gastritis, bile reflux gastritis and atrophic gastritis, has definite therapeutic effects, no toxic or side effect and a low cost and is suitable for promotion and application.